| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |